Skip to main content
. 2020 Nov 16;10:580750. doi: 10.3389/fonc.2020.580750

Figure 5.

Figure 5

Current SOC benefit is enriched in noncystic GBM compared with cystic GBM. (A) Cystic GBM current SOC patients (median OS: 750 days) did not have significantly improved survival compared to cystic GBM not current SOC patients (median OS: 691 days). (B) Noncystic current SOC patients (median OS: 678 days) do show an expected survival benefit compared to noncystic not current SOC patients (median OS: 370 days). (C) Cystic current SOC patients (median OS: 737 days) with known IDH1 wild type do not show a significantly improved survival compared to not current SOC IDH1 wild type cystic GBM patients (median OS: 600 days). (D) Noncystic IDH1 wild type current SOC patients (median OS: 858 days) have a large survival benefit compared to IDH1 wild type noncystic not current SOC patients (median OS: 286 days).